acut
exacerb
ae
sever
complic
idiopath
pulmonari
fibrosi
ipf
intern
work
group
revis
definit
diagnost
criteria
aeipf
new
criteria
aeipf
diagnos
idiopath
trigger
event
result
worsen
respiratori
symptom
widespread
alveolar
damag
current
proven
benefici
manag
strategi
patient
idiopath
trigger
aeipf
first
case
report
show
aeipf
trigger
aspergillu
empyema
success
treat
combin
corticosteroid
system
antifung
therapi
local
antifung
therapi
addit
pharmacolog
therapi
juli
man
refer
hospit
exert
dyspnea
abnorm
chest
xray
find
indic
interstiti
lung
diseas
ild
primari
care
exsmok
packyear
medic
ill
environment
exposur
famili
histori
extrathorac
manifest
suggest
presenc
underli
connect
tissu
diseas
base
integr
clinic
inform
radiolog
find
histopatholog
find
surgic
lung
biopsi
diagnos
ipf
demonstr
gradual
worsen
pulmonari
function
year
forc
vital
capac
pred
april
start
treatment
pirfenidon
result
stabil
pulmonari
function
may
present
histori
cough
dyspnea
initi
vital
sign
reveal
temperatur
respiratori
rate
breath
per
minut
satur
room
air
fine
crackl
heard
bilater
lung
field
laboratori
examin
reveal
white
blood
cell
wbc
count
neutrophil
creactiv
protein
crp
mgdl
comput
tomograph
ct
scan
chest
show
consolid
left
lower
lobe
superimpos
background
honeycomb
pattern
fig
initi
diagnos
bacteri
pneumonia
admit
antimicrobi
therapi
ceftriaxon
azithromycin
signific
bacteria
detect
sputum
smear
cultur
test
day
develop
leftsid
chest
pain
worsen
dyspnea
chest
ct
scan
show
remain
consolid
left
lower
lobe
pleural
effus
pneumothorax
left
side
fig
chest
tube
insert
left
thorac
caviti
symptom
improv
pleural
effus
cultur
http
receiv
decemb
accept
januari
posit
aspergillu
fumigatu
serum
aspergillu
galactomannan
angiten
test
neg
serum
aspergillu
precipit
antibodi
test
posit
diagnosi
aspergillu
empyema
treatment
switch
intraven
voriconazol
vrcz
day
continu
system
antifung
therapi
experienc
worsen
dyspnea
laboratori
examin
reveal
wbc
count
neutrophil
crp
mgdl
level
serum
brain
natriuret
peptid
procalcitonin
pgml
ngml
respect
arteri
blood
ga
analysi
show
pao
torr
paco
torr
via
nasal
cannula
chest
ct
scan
show
new
bilater
widespread
consolid
groundglass
opac
superimpos
background
honeycomb
pattern
fig
consid
find
clinic
cours
diagnos
aeipf
trigger
aspergillu
empyema
treat
combin
corticosteroid
methylprednisolon
follow
titrat
prednisolon
intraven
recombin
human
solubl
thrombomodulin
rhtm
intraven
vrcz
pirfenidon
continu
day
chest
ct
scan
show
improv
bilater
consolid
groundglass
opac
new
right
bulla
effus
left
pleural
effus
chest
tube
insert
right
bulla
left
thorac
caviti
effus
cultur
posit
aspergillu
fumigatu
system
antifung
therapi
switch
intraven
vrcz
intraven
liposom
amphotericinb
poor
resolut
intrathorac
infus
amphotericinb
amphb
ad
gradual
dose
increas
chest
tube
day
cultur
right
bulla
left
pleural
effus
convert
neg
discharg
day
admiss
fig
describ
case
aeipf
trigger
aspergillu
empyema
new
definit
diagnost
criteria
aeipf
includ
acut
clinic
signific
respiratori
deterior
character
evid
new
widespread
alveolar
abnorm
revis
result
difficulti
distinguish
idiopath
event
respiratori
event
trigger
known
caus
infect
postproceduralpostop
drug
toxic
aspir
nevertheless
identifi
trigger
still
import
may
affect
overal
manag
patient
oda
et
al
show
aspergillu
infect
present
aeipf
autopsi
case
report
also
show
aspergillu
infect
seen
patient
acut
respiratori
distress
syndrom
patholog
characterist
diffus
alveolar
damag
similar
aeipf
previou
report
hypothes
inhal
unknown
mycotoxin
somat
antigen
bioactiv
substanc
produc
aspergillu
may
provok
immunolog
respons
lung
although
direct
relev
remain
unknown
aspergillu
infect
may
import
trigger
aeipf
aspergillu
empyema
rare
clinic
entiti
present
case
risk
factor
diabet
chemotherapi
corticosteroid
therapi
interstiti
pneumonia
observ
kurosaki
et
al
show
pulmonari
aspergillosi
major
complic
interstiti
pneumonia
associ
poor
outcom
destruct
airway
airspac
due
ipf
might
also
contribut
persist
eventu
progress
also
present
case
despit
high
mortal
rate
establish
standard
therapi
aspergillu
empyema
system
antifung
therapi
facilit
limit
respons
previou
report
show
case
aspergillu
empyema
success
treat
combin
system
antifung
therapi
local
antifung
therapi
intrathorac
infus
apmhb
surgic
approach
includ
drainag
case
also
poorli
respons
system
antifung
therapi
requir
drainag
local
antifung
therapi
aggress
treatment
approach
may
improv
surviv
case
aspergillu
empyema
yet
proven
pharmacolog
therapi
aeipf
evidencebas
ipf
guidelin
recommend
corticosteroid
therapi
major
patient
aeipf
weak
recommend
lowqual
evid
hand
corticosteroid
therapi
gener
regard
risk
factor
fungal
infect
papiri
et
al
show
avoid
steroid
ipf
patient
may
favor
natur
histori
diseas
even
moment
ae
struggl
dilemma
care
consider
final
decid
use
corticosteroid
addit
sever
investig
report
efficaci
rhtm
aeipf
regul
coagul
pathway
mainli
reduc
thrombinmedi
clot
enhanc
protein
c
activ
anoth
recent
retrospect
studi
aeipf
show
surviv
significantli
better
patient
treat
pirfenidon
control
group
combin
therapi
case
might
associ
favor
outcom
research
discuss
need
determin
whether
immunosuppress
therapi
includ
corticosteroid
perform
infectiontrigg
aeipf
conclus
first
report
describ
aeipf
trigger
aspergillu
empyema
improv
combin
therapi
whether
trigger
aeipf
differ
clinic
cours
therapeut
respons
idiopath
aeipf
remain
unknown
studi
need
determin
optim
strategi
idiopath
trigger
aeipf
author
confirm
known
conflict
interest
associ
public
signific
financi
support
work
could
influenc
outcom
